CA3124872A1 — Tasimelteon for regulating melatonin production
Assigned to Vanda Pharmaceuticals Inc · Expires 2016-03-10 · 10y expired
What this patent protects
The invention relates generally to the regulation of melatonin production and, more particularly, to the use of tasimelteon in the regulation of melatonin production in an individual exhibiting light-induced melatonin production.
USPTO Abstract
The invention relates generally to the regulation of melatonin production and, more particularly, to the use of tasimelteon in the regulation of melatonin production in an individual exhibiting light-induced melatonin production.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.